WAT · Earnings call · 2026Q2T · Full report
Geographic Revenue Performance
WATERS CORP /DE/ · 2026-08-04 · Importance 54 · Surprise 40 · In source text
Second-quarter reported revenue was $690 million in the Americas, $505 million in Europe, and $450 million in Asia. Analytical Sciences growth was led by the U.S., China, and the rest of Asia, each growing double digits or better. China pharma grew double digits in the first half of 2026, accelerating from 6% growth in the prior year and becoming accretive to company growth. China remained a headwind in acquired businesses, with Biosciences China declining 20% in Flow Clinical and Diagnostics China declining 13% in microbiology.
Key facts
- Q2 2026 Americas as-reported revenue: $690 million; Europe: $505 million; Asia: $450 million (total company as reported by geography)
- Biosciences Flow Clinical outside China grew mid-teens in Q2 2026 while China declined 20%
- Analytical Sciences growth led by U.S., China and rest of Asia, each up double digits or better in Q2 2026
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | — | Q2 2026 Americas as-reported revenue: $690 million; Europe: $505 million; Asia: $450 million (total company as reported by geography) |
| revenue | positive | realized | — | Q2 2026 Americas as-reported revenue: $690 million; Europe: $505 million; Asia: $450 million (total company as reported by geography) |
| revenue | positive | realized | — | Q2 2026 Americas as-reported revenue: $690 million; Europe: $505 million; Asia: $450 million (total company as reported by geography) |